Nitroprusside
As of the edition of 20 October 2026, Nitroprusside is a small molecule: marketed, first approved in 1982 (US); acts on GUCY1B1 and GUCY1B2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Nipride
- First approved
- 1 January 1982 (US)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- MARUISHI PHARMACEUTICAL Co., Ltd; 6 holders in all
- Registered trials
- 43, 9 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Mental health; Cancer; Nutrition and metabolism; Blood and lymph
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Nitroprusside.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 17 | 11 | 3 | 0 |
| Phase 1 | 12 | 6 | 2 | 2 |
| Phase 2 | 10 | 5 | 1 | 4 |
| Phase 4 | 4 | 0 | 0 | 3 |
| All trials | 43 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Acquired holder | 2004 to now |
| AbbVie | Acquired holder | 2012 to now |
| Exela Pharma Sciences | Later holder | 2017 to now |
| Abbott | Later holder | |
| Roche | Applicant |